Topical Pioglitazone Nanoformulation for the Treatment of Atopic Dermatitis: Design, Characterization and E cacy in Hairless Mouse Model
MetadataShow full item record
Atopic dermatitisPioglitazoneNanoemulsionPluronic F-127
Espinoza, L. C., Vera-García, R., Silva-Abreu, M., Domènech, Ò., Badia, J., Rodríguez-Lagunas, M. J., ... & Calpena, A. C. (2020). Topical Pioglitazone Nanoformulation for the Treatment of Atopic Dermatitis: Design, Characterization and Efficacy in Hairless Mouse Model. Pharmaceutics, 12(3), 255.
SponsorshipThis work was supported by Secretaría de Educación Superior, Ciencia, Tecnología e Innovación (SENESCYT—Ecuador) (grant number 073-CIBAE-2015).
Pioglitazone (PGZ) is a drug used to treat type 2 diabetes mellitus that has been reported to show additional therapeutic activities on diverse inflammatory parameters. The aim of this study was to optimize a topical PGZ-loaded nanoemulsion (PGZ-NE) in order to evaluate its effectiveness for treating atopic dermatitis (AD). The composition of the nanoformulation was established by pseudo-ternary diagram. Parameters such as physical properties, stability, in vitro release profile, and ex vivo permeation were determined. The efficacy study was carried out using oxazolone-induced AD model in hairless mice. PGZ-NE released the drug following a hyperbolic kinetic. Additionally, its properties provided high retention potential of drug inside the skin. Therapeutic benefits of PGZ-NE were confirmed on diverse events of the inflammatory process, such as reduction of lesions, enhancement of skin barrier function, diminished infiltration of inflammatory cells, and expression of pro-inflammatory cytokines. These results were reinforced by atomic force microscope (AFM), which demonstrated the ability of the formulation to revert the rigidification caused by oxazolone and consequently improve the elasticity of the skin. These results suggest that PGZ-NE may be a promising treatment for inflammatory dermatological conditions such as AD.